Risks and benefits of articular gene therapy

Joint Bone Spine

Volumn 70, Issue 6, 2003, Pages 486-488

  Boissier, Marie Christophe ^a   Bessis, Natacha ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Biotherapy; Gene therapy; Rheumatoid arthritis; Side effects

Indexed keywords

ARTICULAR GENE THERAPY; CONFERENCE PAPER; GENE THERAPY; IMMUNE RESPONSE; JOINT CAPSULE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0346102678     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.07.002     Document Type: Conference Paper

References (7)

1. Noguchi P. Risks and benefits of gene therapy. New Engl J Med 2003;348:193-4.
2. Bessis N, Doucet C, Cottard V, Douar AM, Firat H, Jorgensen C, et al. Gene therapy for rheumatoid arthritis. J Gene Med 2002;4:581-91.
3. Boissier MC. Pondering the precautionary principle. Joint Bone Spine 2003;70 [in press].
4. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wullfraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 2003;348:255-6.
5. Lemoine NR. Risks and benefits of gene therapy for immunodeficiency: a reality check. Gene Ther 2002;9:1561-2.
6. Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 1999;96:2615-20.
7. Boissier MC. Ethical aspects of gene therapy in rheumatology. Jt Bone Spine 2001;68:109-11.